|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Tenecteplase#Structure]] |
| {{Tenecteplase}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| ==Description==
| | [[Category: Cardiovascular Drugs]] |
| TNKase® (Tenecteplase) is a [[tissue plasminogen activator]] ([[tPA]]) produced by recombinant DNA technology using an established mammalian cell line (Chinese Hamster Ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of [[threonine]] 103 with [[asparagine]], and a substitution of [[asparagine]] 117 with [[glutamine]], both within the kringle 1 domain, and a [[tetra-alanine]] substitution at amino acids 296–299 in the protease domain. Cell culture is carried out in nutrient medium containing the antibiotic [[gentamicin]] (65 mg/L). However, the presence of the antibiotic is not detectable in the final product (limit of detection is 0.67 µg/vial). TNKase is a sterile, white to off-white, lyophilized powder for single intravenous (IV) bolus administration after reconstitution with Sterile Water for Injection (SWFI), USP. Each vial of TNKase nominally contains 52.5 mg Tenecteplase, 0.55 g L-arginine, 0.17 g [[phosphoric acid]], and 4.3 mg [[polysorbate]] 20, which includes a 5% overfill. Each vial will deliver 50 mg of Tenecteplase.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TNKASE (TENECTEPLASE) KIT [GENENTECH, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69e391bf-1250-4083-aa60-6aa41c33657f | publisher = | date = | accessdate = 6 February 2014 }}</ref>
| | [[Category: Drug]] |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Thrombolytic drugs]]
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |